Multiple pathways for Epstein-Barr virus episome loss from nasopharyngeal carcinoma
✍ Scribed by Dirk P. Dittmer; Chelsey J. Hilscher; Margaret L. Gulley; Eric V. Yang; Min Chen; Ronald Glaser
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- French
- Weight
- 469 KB
- Volume
- 123
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Epstein‐Barr virus (EBV) is the prototypical example for episomal persistence of genetic information. Yet, little is known about how this viral episome is lost. Episome loss occurs naturally in nasopharyngeal carcinoma (NPC) upon explantation into culture. Using whole‐genome profiling, we found evidence for 2 different pathways of episome loss: (i) rapid loss of the entire episome or (ii) successive mutation/deletion of the episome until at least 1 essential cis‐element is destroyed. This second phenotype was seen in a clone of HONE‐1 NPC cells that maintains the EBV episome for prolonged time in culture. The conceptual insights provided by our quantitative analysis should aid our understanding of mammalian episomes, as well as lead to designs to cure latent viral infection. © 2008 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Tumor cells from NPC patients are regularly and latently infected with EBV. To examine whether the virus serves as target for immune intervention of the cancer, we determined levels of EBV-specific CTLp in peripheral blood from NPC patients, long-term survivors of the cancer and healthy subjects. CT
## Abstract The Epstein–Barr virus (EBV) early antigen (EA) complex consists of multiple proteins with relevance for diagnosis of acute, chronic and malignant EBV related diseases, including nasopharyngeal carcinoma (NPC). In a recent study, it was found that the molecular diversity of EBV‐specific
## Abstract An immunoautoradiographic method was used for the detection of EB virus lgA/EA antibody in sera from NPC patients and other control groups. Ninety‐six percent of NPC patients had IgA/EA antibody with a high titer of GMT. The positive rates of IgA/EA antibody in patients with malignant t